



Corrigendum



Corrigendum to “Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage ovarian cancer: A retrospective cohort study” [Eur J Cancer 222 (2025) 115472]

Luke Steventon^{a,b}, Shibani Nicum^b, Pinkie Chambers^{a,b}, Kenneth Man^a, David Dodwell^c, Zhe Wang^c, Apini Patel^b, Ben Pickwell-Smith^{d,e}, Li Wei^{a,*}

^a Research Department of Practice and Policy, UCL School of Pharmacy, Mezzanine Floor, BMA House, Tavistock Square, London WC1H 9JP, United Kingdom

^b University College London Hospital NHS Foundation Trust, 235 Euston Road, London NW1 2BU, United Kingdom

^c Nuffield Department of Population Health, University of Oxford, Roosevelt Drive, Headington, Oxford OX3 7LH, United Kingdom

^d Leeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF, United Kingdom

^e Medical Oncology Department, University of Leeds, Leeds LS9 7LP, United Kingdom

The authors regret that minor corrections to Table 1 and Fig. 1 are required.

The figures for PARPi treatment in Table 1 have been corrected. The gridlines in Fig. 1 were not clear.

DOI of original article: <https://doi.org/10.1016/j.ejca.2025.115472>.

* Corresponding author.

E-mail address: l.wei@ucl.ac.uk (L. Wei).

<https://doi.org/10.1016/j.ejca.2025.115492>

Available online 16 May 2025

0959-8049/© 2025 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Table 1

Baseline characteristics of the study cohort by chemotherapy only and chemotherapy + poly(ADP-ribose) polymerase inhibitor treatment groups.

Characteristic, n, (%)	Overall N = 11,531 ^a	Chemotherapy only N = 10,002 ^a	Chemotherapy + PARPiN = 1529 ^a
Age at start of treatment, median, years (IQR)	68 (59, 75)	69 (60, 76)	63 (55, 70)
< 50	1057 (9.2 %)	857 (8.6 %)	200 (13 %)
50–60	2122 (18 %)	1687 (17 %)	435 (28 %)
60–70	3593 (31 %)	3048 (30 %)	545 (36 %)
> 70	4759 (41 %)	4410 (44 %)	349 (23 %)
Cancer stage, n (%)			
3	694 (6.0 %)	621 (6.2 %)	73 (4.8 %)
3A	638 (5.5 %)	562 (5.6 %)	76 (5.0 %)
3B	715 (6.2 %)	616 (6.2 %)	99 (6.5 %)
3 C	5188 (45 %)	4477 (45 %)	711 (47 %)
4	2503 (22 %)	2237 (22 %)	266 (17 %)
4A	594 (5.2 %)	531 (5.3 %)	63 (4.1 %)
4B	954 (8.3 %)	824 (8.2 %)	130 (8.5 %)
Advanced (unspecified)	245 (2.1 %)	134 (1.3 %)	111 (7.3 %)
Body mass index, median (IQR)	26.0 (22.8, 30.1)	25.9 (22.7, 29.8)	26.8 (23.2, 31.2)
Index of multiple deprivation			
1 - most deprived	1728 (15 %)	1543 (15 %)	185 (12 %)
2	2085 (18 %)	1826 (18 %)	259 (17 %)
3	2496 (22 %)	2166 (22 %)	330 (22 %)
4	2591 (22 %)	2260 (23 %)	331 (22 %)
5 - least deprived	2631 (23 %)	2207 (22 %)	424 (28 %)
Ethnicity			
Asian	418 (3.6 %)	356 (3.6 %)	62 (4.1 %)
Black	178 (1.5 %)	151 (1.5 %)	27 (1.8 %)
Mixed Race	42 (0.4 %)	37 (0.4 %)	5 (0.3 %)
Other	148 (1.3 %)	120 (1.2 %)	28 (1.8 %)
Unknown	328 (2.8 %)	280 (2.8 %)	48 (3.1 %)
White	10,417 (90 %)	9058 (91 %)	1359 (89 %)
Region			
East of England	1359 (12 %)	1176 (12 %)	183 (12 %)
London	1551 (13 %)	1290 (13 %)	261 (17 %)
Midlands	1771 (15 %)	1611 (16 %)	160 (10 %)
North East & Yorkshire	2059 (18 %)	1793 (18 %)	266 (17 %)
North West	1467 (13 %)	1246 (12 %)	221 (14 %)
South East	1877 (16 %)	1633 (16 %)	244 (16 %)
South West	1446 (13 %)	1252 (13 %)	194 (13 %)
Missing/Unknown	1	1	-
Chemotherapy regimen (first-line)			
Carboplatin + paclitaxel	8384 (73 %)	6997 (70 %)	1387 (90 %)
Carboplatin single agent	2975 (26 %)	2845 (28 %)	130 (9 %)
Other first-line chemotherapy regimen	172 (1 %)	160 (2 %)	12 (1 %)
PARPi treatment			
Niraparib	1108 (72 %)	-	1108 (72 %)
Olaparib	368 (24 %)	-	368 (24 %)
Rucaparib	53 (4 %)	-	53 (4 %)

Median (IQR).

^a n (%).




Fig. 1. Flowchart showing specification of study population by exclusion criteria.

The authors would like to apologise for any inconvenience caused.
Amended Table 1:

Amended Fig. 1: